Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Tarsus Pharmaceuticals, Inc. (TARS)
since 2020 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Tarsus Pharmaceuticals, Inc..
(See page 1 of this report.) Table 2 shows the detailed insider transactions.
This company's CIK number is 1819790.
Total stock buying since 2020: $16,548,060.
Total stock sales since 2020: $59,553,855.
Total stock option exercises since 2020: $129,943.
Table 3. Detailed insider trading at Tarsus Pharmaceuticals, Inc. (TARS) , Part 2
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2023-03-21 | Mottiwala Aziz (Chief Commercial Officer) | Sale | 349 | 12.89 | 4,498 |
| 2023-03-21 | Trevejo Jose M. (CHIEF MEDICAL OFFICER) | Sale | 519 | 12.89 | 6,689 |
| 2023-03-21 | Greenstein Leonard M. (Chief Financial Officer) | Sale | 326 | 12.89 | 4,202 |
| 2023-03-20 | Wahl Bryan (General Counsel) | Sale | 357 | 12.61 | 4,501 |
| 2023-03-20 | Whitfield Dianne C. (Chief Human Resources Officer) | Sale | 333 | 12.61 | 4,199 |
| 2023-03-20 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 741 | 12.61 | 9,344 |
| 2023-03-20 | Neervannan Seshadri (Chief Operating Officer) | Sale | 380 | 12.61 | 4,791 |
| 2023-03-20 | Holdbrook Mark J. (V.P., Clinical Affairs) | Sale | 198 | 12.61 | 2,496 |
| 2023-03-20 | Mottiwala Aziz (Chief Commercial Officer) | Sale | 358 | 12.61 | 4,514 |
| 2023-03-20 | Trevejo Jose M. (CHIEF MEDICAL OFFICER) | Sale | 530 | 12.61 | 6,683 |
| 2023-03-20 | Greenstein Leonard M. (Chief Financial Officer) | Sale | 333 | 12.61 | 4,199 |
| 2023-03-17 | Wahl Bryan (General Counsel) | Sale | 339 | 13.28 | 4,501 |
| 2023-03-17 | Whitfield Dianne C. (Chief Human Resources Officer) | Sale | 316 | 13.28 | 4,196 |
| 2023-03-17 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 795 | 13.28 | 10,557 |
| 2023-03-17 | Neervannan Seshadri (Chief Operating Officer) | Sale | 360 | 13.28 | 4,780 |
| 2023-03-17 | Holdbrook Mark J. (V.P., Clinical Affairs) | Sale | 188 | 13.28 | 2,496 |
| 2023-03-17 | Mottiwala Aziz (Chief Commercial Officer) | Sale | 339 | 13.28 | 4,501 |
| 2023-03-17 | Trevejo Jose M. (CHIEF MEDICAL OFFICER) | Sale | 504 | 13.28 | 6,693 |
| 2023-03-17 | Greenstein Leonard M. (Chief Financial Officer) | Sale | 316 | 13.28 | 4,196 |
| 2023-03-16 | Wahl Bryan (General Counsel) | Sale | 674 | 13.43 | 9,050 |
| 2023-03-16 | Whitfield Dianne C. (Chief Human Resources Officer) | Sale | 626 | 13.43 | 8,406 |
| 2023-03-16 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 791 | 13.43 | 10,623 |
| 2023-03-16 | Neervannan Seshadri (Chief Operating Officer) | Sale | 714 | 13.43 | 9,588 |
| 2023-03-16 | Holdbrook Mark J. (V.P., Clinical Affairs) | Sale | 374 | 13.43 | 5,022 |
| 2023-03-16 | Mottiwala Aziz (Chief Commercial Officer) | Sale | 672 | 13.43 | 9,024 |
| 2023-03-16 | Trevejo Jose M. (Chief Medical Officer) | Sale | 998 | 13.43 | 13,402 |
| 2023-03-16 | Greenstein Leonard M. (Chief Financial Officer) | Sale | 5,313 | 13.44 | 71,380 |
| 2023-03-15 | Wahl Bryan (General Counsel) | Option Ex | 9,580 | .00 | 0 |
| 2023-03-15 | Whitfield Dianne C. (Chief Human Resources Officer) | Option Ex | 8,924 | .00 | 0 |
| 2023-03-15 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 8,000 | 13.79 | 110,320 |
| 2023-03-15 | Azamian Bobak R. (President/CEO and Board Chair) | Option Ex | 11,299 | .00 | 0 |
| 2023-03-15 | Neervannan Seshadri (Chief Operating Officer) | Option Ex | 10,194 | .00 | 0 |
| 2023-03-15 | Holdbrook Mark J. (V.P., Clinical Affairs) | Option Ex | 5,306 | .00 | 0 |
| 2023-03-15 | Mottiwala Aziz (Chief Commercial Officer) | Option Ex | 9,580 | .00 | 0 |
| 2023-03-15 | Trevejo Jose M. (Chief Medical Officer) | Option Ex | 15,098 | .00 | 0 |
| 2023-03-15 | Greenstein Leonard M. (Chief Financial Officer) | Option Ex | 4,462 | .00 | 0 |
| 2023-03-09 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 717 | 15.01 | 10,762 |
| 2023-03-08 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 4,853 | 15.02 | 72,892 |
| 2023-02-16 | Greenstein Leonard M. (Chief Financial Officer) | Sale | 5,000 | 15.12 | 75,600 |
| 2023-02-15 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 8,000 | 15.28 | 122,240 |
| 2023-02-08 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 9,000 | 15.14 | 136,260 |
| 2023-01-23 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 4,856 | 15.45 | 75,025 |
| 2023-01-20 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 240 | 15.00 | 3,600 |
| 2023-01-19 | Greenstein Leonard M. (Chief Financial Officer) | Sale | 5,000 | 14.56 | 72,800 |
| 2023-01-18 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 8,000 | 14.56 | 116,480 |
| 2023-01-11 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 3,904 | 15.11 | 58,989 |
| 2023-01-10 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 905 | 15.17 | 13,728 |
| 2023-01-09 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 729 | 15.15 | 11,044 |
| 2023-01-06 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 411 | 15.00 | 6,165 |
| 2022-12-21 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 8,000 | 14.57 | 116,560 |
| 2022-12-16 | Azamian Bobak R. (President/CEO and Board Chair) | Sale | 535 | 15.01 | 8,030 |
| 2022-12-02 | Wahl Bryan (General Counsel) | Sale | 1,154 | 16.90 | 19,502 |
| 2022-12-02 | Whitfield Dianne C. (Chief Human Resources Officer) | Sale | 1,154 | 16.90 | 19,502 |
| 2022-12-01 | Wahl Bryan (General Counsel) | Sale | 1,164 | 16.75 | 19,497 |
| 2022-12-01 | Whitfield Dianne C. (Chief Human Resources Officer) | Sale | 1,165 | 16.75 | 19,513 |
| 2022-11-30 | Wahl Bryan (General Counsel) | Sale | 1,183 | 16.50 | 19,519 |
| 2022-11-30 | Whitfield Dianne C. (Chief Human Resources Officer) | Sale | 1,182 | 16.50 | 19,503 |
| 2022-11-29 | Wahl Bryan (General Counsel) | Option Ex | 10,251 | .00 | 0 |
| 2022-11-29 | Whitfield Dianne C. (Chief Human Resources Officer) | Option Ex | 10,251 | .00 | 0 |
| 2022-11-17 | Greenstein Leonard M. (Chief Financial Officer) | Sale | 5,000 | 16.54 | 82,700 |
| 2022-11-16 | Azamian Bobak R. (President and CEO) | Sale | 8,000 | 17.06 | 136,480 |
| 2022-11-15 | Mottiwala Aziz (Chief Commercial Officer) | Sale | 20,571 | 17.72 | 364,518 |
| 2022-10-20 | Greenstein Leonard M. (Chief Financial Officer) | Sale | 5,000 | 16.26 | 81,300 |
| 2022-10-19 | Azamian Bobak R. (President and CEO) | Sale | 24,000 | 17.25 | 414,120 |
| 2022-10-12 | Azamian Bobak R. (President and CEO) | Sale | 9,000 | 16.00 | 144,000 |
| 2022-09-21 | Azamian Bobak R. (President and CEO) | Sale | 8,000 | 16.67 | 133,384 |
| 2022-06-15 | Ackermann Michael (Director) | Option Ex | 4,257 | .00 | 0 |
| 2022-05-05 | Ackermann Michael (Director) | Buy | 100,000 | 13.50 | 1,350,000 |
| 2022-05-05 | Vivo Capital Fund Ix, L.p. | Sale | 5,374 | 12.25 | 65,831 |
| 2022-05-04 | Vivo Capital Fund Ix, L.p. | Sale | 19,738 | 12.67 | 250,080 |
| 2022-05-03 | Vivo Capital Fund Ix, L.p. | Sale | 451,418 | 13.25 | 5,981,288 |
| 2022-05-02 | Vivo Capital Fund Ix, L.p. | Sale | 41,800 | 15.19 | 634,942 |
| 2021-12-01 | Azamian Bobak R. (President and CEO) | Sale | 5,833 | 25.30 | 147,604 |
| 2021-12-01 | Ackermann Michael | Sale | 5,833 | 25.26 | 147,359 |
| 2021-11-08 | Mottiwala Aziz (Chief Commercial Officer) | Sale | 1,889 | 28.11 | 53,099 |
| 2021-11-05 | Mottiwala Aziz (Chief Commercial Officer) | Sale | 11 | 28.11 | 309 |
| 2021-11-04 | Mottiwala Aziz (Chief Commercial Officer) | Sale | 100 | 28.03 | 2,803 |
| 2021-11-02 | Mottiwala Aziz (Chief Commercial Officer) | Sale | 6,000 | 26.91 | 161,472 |
| 2021-11-01 | Azamian Bobak R. (President and CEO) | Sale | 5,833 | 27.98 | 163,236 |
| 2021-11-01 | Ackermann Michael | Sale | 5,833 | 27.97 | 163,149 |
| 2021-10-12 | Azamian Bobak R. (President and CEO) | Sale | 5,531 | 25.96 | 143,612 |
| 2021-10-12 | Ackermann Michael | Sale | 5,633 | 26.00 | 146,486 |
| 2021-10-08 | Azamian Bobak R. (President and CEO) | Sale | 302 | 25.02 | 7,555 |
| 2021-10-08 | Ackermann Michael | Sale | 200 | 25.03 | 5,006 |
| 2021-09-10 | Mottiwala Aziz (Chief Commercial Officer) | Sale | 2,593 | 22.15 | 57,434 |
| 2021-09-10 | Mottiwala Aziz (Chief Commercial Officer) | Option Ex | 6,943 | 5.72 | 39,713 |
| 2021-09-01 | Azamian Bobak R. (President and CEO) | Sale | 5,833 | 25.82 | 150,584 |
| 2021-09-01 | Ackermann Michael (Director) | Sale | 5,833 | 25.24 | 147,236 |
| 2021-08-11 | Azamian Bobak R. (President and CEO) | Sale | 1,917 | 25.07 | 48,061 |
| 2021-08-11 | Ackermann Michael (Director) | Sale | 621 | 25.15 | 15,619 |
| 2021-08-10 | Azamian Bobak R. (President and CEO) | Sale | 103 | 25.00 | 2,575 |
| 2021-08-09 | Azamian Bobak R. (President and CEO) | Sale | 827 | 25.07 | 20,728 |
| 2021-08-09 | Ackermann Michael (Director) | Sale | 700 | 25.00 | 17,500 |
| 2021-08-06 | Azamian Bobak R. (President and CEO) | Sale | 1,616 | 25.00 | 40,400 |
| 2021-08-06 | Ackermann Michael (Director) | Sale | 3,129 | 25.00 | 78,225 |
| 2021-08-05 | Azamian Bobak R. (President and CEO) | Sale | 1,370 | 25.00 | 34,250 |
| 2021-08-05 | Ackermann Michael (Director) | Sale | 1,383 | 25.00 | 34,581 |
| 2021-06-25 | Vivo Capital Fund Ix, L.p. | Sale | 7,704 | 29.60 | 228,038 |
| 2021-06-24 | Vivo Capital Fund Ix, L.p. | Sale | 10,000 | 29.90 | 299,000 |
| 2021-06-23 | Vivo Capital Fund Ix, L.p. | Sale | 37,980 | 29.80 | 1,131,804 |
| 2021-06-22 | Vivo Capital Fund Ix, L.p. | Sale | 110,000 | 28.50 | 3,135,000 |
| 2021-06-21 | Vivo Capital Fund Ix, L.p. | Sale | 91,620 | 29.70 | 2,721,114 |
| 2021-05-07 | Wong Roderick | Sale | 450,000 | 29.98 | 13,491,000 |
| 2021-04-14 | Vivo Capital Fund Ix, L.p. | Sale | 400 | 30.37 | 12,148 |
| 2020-10-20 | Horowitz Limited Partnership Viii (10% Owner) | Buy | 184,375 | 16.00 | 2,950,000 |
| 2020-10-20 | Tester Jason E. (Director) | Buy | 171,875 | 16.00 | 2,750,000 |
| 2020-10-20 | Vivo Capital Fund Ix, L.p. (10% Owner) | Buy | 250,000 | 16.00 | 4,000,000 |
| 2020-10-20 | Heron Patrick J (10% Owner) | Buy | 312,500 | 16.00 | 5,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
of TARS listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Tarsus Pharmaceuticals, Inc. (symbol TARS,
CIK number 1819790) see
the Securities and Exchange Commission (SEC) website.